Press Resease

Scleroderma Diagnostics and Therapeutics Market by Drug Class (Immunosuppressive Agents, Corticosteroids, Endothelin Receptor Agonists, Calcium Channel Blockers, Chelating Agents, PDE-5 Inhibitors, H2 Blockers, Prostacyclin Analogues, ACE Inhibitors, and Proton Pump Inhibitors), by Indication (Systemic and Localized), and by Diagnostic Test Type (Imaging Techniques, Skin Biopsy, Electrocardiogram and Echocardiogram, Pulmonary Function Tests, and Blood Test): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024

Published Date: 10-Sep-2018 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3321 Status : Published

Global scleroderma diagnostics and therapeutics market expected to generate revenue of around USD 3,165.85 million by end of 2024, growing at a CAGR of around 10.21% between 2018 and 2024. Scleroderma is an autoimmune condition that is characterized by hard and thickened skin along with blood vessel problems.

Description

The report covers forecast and analysis for the scleroderma diagnostics and therapeutics market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the scleroderma diagnostics and therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the scleroderma diagnostics and therapeutics market on a global as well as regional level.

In order to give the users of this report a comprehensive view of the scleroderma diagnostics and therapeutics market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein segmental segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Scleroderma Diagnostics and Therapeutics Market

The report provides company market share analysis in order to give a broader overview of the key players in the scleroderma diagnostics and therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug class launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the scleroderma diagnostics and therapeutics market on the global and regional basis. 

The study provides a decisive view of the scleroderma diagnostics and therapeutics market by segmenting the market based on drug class, indication, diagnostic test type, and regions. The segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The drug class segment has been segmented into immunosuppressive agents, corticosteroids, endothelin receptor agonists, calcium channel blockers, chelating agents, PDE-5 inhibitors, H2 blockers, prostacyclin analogs, ACE inhibitors, and proton pump inhibitors. Based on the indication, scleroderma diagnostics and therapeutics market have been segmented into systemic and localized. Based on diagnostic test type, scleroderma diagnostics and therapeutics market have been segmented into imaging techniques, skin biopsy, electrocardiogram and echocardiogram, pulmonary function tests, and blood test.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S. Canada, Germany, France, the UK, China, Japan, India, and Brazil. This segmentation includes demand for scleroderma diagnostics and therapeutics based on individual segment and applications in all the regions and countries.

The report also includes detailed profiles of end players such as Bayer AG, Allergan, Inc., Active Biotech AB, BioLineRx, Ltd., Digna Biotech, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Vida Therapeutics Inc., Angion Biomedica Corp., Daval International Ltd., Corbus Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd. among others.

This report segments the global scleroderma diagnostics and therapeutics market as follows:

Global Scleroderma Diagnostics and Therapeutics Market: By Drug Class

  • Immunosuppressive Agents
  • Corticosteroids
  • Endothelin Receptor Agonists
  • Calcium Channel Blockers
  • Chelating Agents
  • PDE-5 Inhibitors
  • H2 Blockers
  • Prostacyclin Analogues
  • ACE Inhibitors
  • Proton Pump Inhibitors

Global Scleroderma Diagnostics and Therapeutics Market: By Indication

  • Systemic
  • Localized

Global Scleroderma Diagnostics and Therapeutics Market: By Diagnostic Test Type

  • Imaging Techniques
  • Skin Biopsy
  • Electrocardiogram and Echocardiogram
  • Pulmonary Function Tests
  • Blood Test

Global Scleroderma Diagnostics and Therapeutics Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Scleroderma Diagnostics and Therapeutics market, 2017 - 2024 (USD Million)
    • 2.2. Global Scleroderma Diagnostics and Therapeutics market : Snapshot
  •  
  • Chapter 3. Scleroderma Diagnostics and Therapeutics Market - Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Scleroderma Diagnostics and Therapeutics market drivers: Impact analysis
      • 3.2.2. Rising incidence of scleroderma
      • 3.2.3. Increasing frequency of genetic mutations
    • 3.3. Market restraints
      • 3.3.1. Unfavorable drug effects
      • 3.3.2. Ironclad government regulations
    • 3.4. Opportunities
      • 3.4.1. Extensive R&D related to diagnosis and treatment of scleroderma
      • 3.4.2. Development of new therapeutic methods
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by drug class segment
      • 3.6.2. Market attractiveness analysis, by indication segment
      • 3.6.3. Market attractiveness analysis, by diagnostic test type segment
  •  
  • Chapter 4. Global Scleroderma Diagnostics and Therapeutics Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Scleroderma Diagnostics and Therapeutics market: company market share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Drug Class Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global Scleroderma Diagnostics and Therapeutics Market - Drug Class Segment Analysis
    • 5.1. Global Scleroderma Diagnostics and Therapeutics market: Drug Class overview
      • 5.1.1. Global Scleroderma Diagnostics and Therapeutics market revenue share, by Drug Class, 2017 and 2024
    • 5.2. Immunosuppressive Agents
      • 5.2.1. Global Scleroderma Diagnostics and Therapeutics market for Immunosuppressive Agents, 2017 - 2024 (USD Million)
    • 5.3. Corticosteroids
      • 5.3.1. Global Scleroderma Diagnostics and Therapeutics market for Corticosteroids, 2017 - 2024 (USD Million)
    • 5.4. Endothelin Receptor Agonists
      • 5.4.1. Global Scleroderma Diagnostics and Therapeutics market for Endothelin Receptor Agonists, 2017 - 2024 (USD Million)
    • 5.5. Calcium Channel Blockers
      • 5.5.1. Global Scleroderma Diagnostics and Therapeutics market for Calcium Channel Blockers, 2017 - 2024 (USD Million)
    • 5.6. Chelating Agents
      • 5.6.1. Global Scleroderma Diagnostics and Therapeutics market for Chelating Agents, 2017 - 2024 (USD Million)
    • 5.7. PDE-5 Inhibitors
      • 5.7.1. Global Scleroderma Diagnostics and Therapeutics market for PDE-5 Inhibitors, 2017 - 2024 (USD Million)
    • 5.8. H2 Blockers
      • 5.8.1. Global Scleroderma Diagnostics and Therapeutics market for H2 Blockers, 2017 - 2024 (USD Million)
    • 5.9. Prostacyclin Analogues
      • 5.9.1. Global Scleroderma Diagnostics and Therapeutics market for Prostacyclin Analogues, 2017 - 2024 (USD Million)
    • 5.10. ACE Inhibitors
      • 5.10.1. Global Scleroderma Diagnostics and Therapeutics market for ACE Inhibitors, 2017 - 2024 (USD Million)
    • 5.11. Proton Pump Inhibitors
      • 5.11.1. Global Scleroderma Diagnostics and Therapeutics market for Proton Pump Inhibitors, 2017 - 2024 (USD Million)
  •  
  • Chapter 6. Global Scleroderma Diagnostics and Therapeutics Market - Indication Segment Analysis
    • 6.1. Global Scleroderma Diagnostics and Therapeutics market: Indication overview
      • 6.1.1. Global Scleroderma Diagnostics and Therapeutics market revenue share, by Indication, 2017 and 2024
    • 6.2. Systemic
      • 6.2.1. Global Scleroderma Diagnostics and Therapeutics market for Systemic, 2017 - 2024 (USD Million)
    • 6.3. Localized
      • 6.3.1. Global Scleroderma Diagnostics and Therapeutics market for Localized, 2017 - 2024 (USD Million)
  •  
  • Chapter 7. Global Scleroderma Diagnostics and Therapeutics Market - Diagnostic Test Type Segment Analysis
    • 7.1. Global Scleroderma Diagnostics and Therapeutics market: Diagnostic Test Type overview
      • 7.1.1. Global Scleroderma Diagnostics and Therapeutics market revenue share, by Diagnostic Test Type, 2017 and 2024
    • 7.2. Imaging Techniques
      • 7.2.1. Global Scleroderma Diagnostics and Therapeutics market for Imaging Techniques, 2017 - 2024 (USD Million)
    • 7.3. Skin Biopsy
      • 7.3.1. Global Scleroderma Diagnostics and Therapeutics market for Skin Biopsy, 2017 - 2024 (USD Million)
    • 7.4. Electrocardiogram and Echocardiogram
      • 7.4.1. Global Scleroderma Diagnostics and Therapeutics market for Electrocardiogram and Echocardiogram, 2017 - 2024 (USD Million)
    • 7.5. Pulmonary Function Tests
      • 7.5.1. Global Scleroderma Diagnostics and Therapeutics market for Pulmonary Function Tests, 2017 - 2024 (USD Million)
    • 7.6. Blood Test
      • 7.6.1. Global Scleroderma Diagnostics and Therapeutics market for Blood Test, 2017 - 2024 (USD Million)
  •  
  • Chapter 8. Global Scleroderma Diagnostics and Therapeutics Market - Regional Segment Analysis
    • 8.1. Global Scleroderma Diagnostics and Therapeutics market: Regional overview
      • 8.1.1. Global Scleroderma Diagnostics and Therapeutics market revenue share, by region, 2017 and 2024
    • 8.2. North America
      • 8.2.1. North America Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
      • 8.2.2. North America Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
      • 8.2.3. North America Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.2.4. U.S.
        • 8.2.4.1. U.S. Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.2.4.2. U.S. Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.2.4.3. U.S. Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.2.5. Canada
        • 8.2.5.1. Canada Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.2.5.2. Canada Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.2.5.3. Canada Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.2.6.2. Rest of North America Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.2.6.3. Rest of North America Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
      • 8.3.2. Europe Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
      • 8.3.3. Europe Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.3.4. Germany
        • 8.3.4.1. Germany Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.3.4.2. Germany Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.3.4.3. Germany Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.3.5. U.K.
        • 8.3.5.1. U.K. Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.3.5.2. U.K. Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.3.5.3. U.K. Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.3.6.2. France Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.3.6.3. France Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.3.7. Italy
        • 8.3.7.1. Italy Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.3.7.2. Italy Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.3.7.3. Italy Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.3.8. Spain
        • 8.3.8.1. Spain Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.3.8.2. Spain Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.3.8.3. Spain Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.3.9. Russia
        • 8.3.9.1. Russia Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.3.9.2. Russia Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.3.9.3. Russia Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.3.10. Rest of Europe
        • 8.3.10.1. Rest of Europe Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.3.10.2. Rest of Europe Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.3.10.3. Rest of Europe Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
      • 8.4.2. Asia Pacific Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
      • 8.4.3. Asia Pacific Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.4.4.2. China Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.4.4.3. China Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.4.5.2. Japan Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.4.5.3. Japan Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.4.6.2. India Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.4.6.3. India Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.4.7. Australia
        • 8.4.7.1. Australia Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.4.7.2. Australia Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.4.7.3. Australia Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.4.8.2. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.4.8.3. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
      • 8.5.2. Latin America Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
      • 8.5.3. Latin America Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.5.4.2. Brazil Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.5.4.3. Brazil Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.5.5. Mexico
        • 8.5.5.1. Mexico Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.5.5.2. Mexico Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.5.5.3. Mexico Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.5.6. Argentina
        • 8.5.6.1. Argentina Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.5.6.2. Argentina Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.5.6.3. Argentina Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.5.7. Rest of Latin America
        • 8.5.7.1. Rest of Latin America Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.5.7.2. Rest of Latin America Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.5.7.3. Rest of Latin America Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
    • 8.6. Middle East and Africa
      • 8.6.1. Middle East and Africa Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
      • 8.6.2. Middle East and Africa Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
      • 8.6.3. Middle East and Africa Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.6.4. Saudi Arabia
        • 8.6.4.1. Saudi Arabia Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.6.4.2. Saudi Arabia Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.6.4.3. Saudi Arabia Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.6.5. UAE
        • 8.6.5.1. UAE Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.6.5.2. UAE Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.6.5.3. UAE Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.6.6. South Africa
        • 8.6.6.1. South Africa Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.6.6.2. South Africa Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.6.6.3. South Africa Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.6.7. Qatar
        • 8.6.7.1. Qatar Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.6.7.2. Qatar Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.6.7.3. Qatar Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
      • 8.6.8. Rest of Middle East and Africa
        • 8.6.8.1. Rest of Middle East and Africa Scleroderma Diagnostics and Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.6.8.2. Rest of Middle East and Africa Scleroderma Diagnostics and Therapeutics market revenue, by Indication, 2017 - 2024 (USD Million)
        • 8.6.8.3. Rest of Middle East and Africa Scleroderma Diagnostics and Therapeutics market revenue, by Diagnostic Test Type, 2017 - 2024 (USD Million)
  •  
  • Chapter 9. Company Profile
    • 9.1. Bayer AG
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Therapy portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Allergan, Inc.
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Therapy portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Active Biotech AB
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Therapy portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. BioLineRx, Ltd.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Therapy portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Digna Biotech
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Therapy portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Bristol-Myers Squibb Company
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Therapy portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. GlaxoSmithKline plc
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Therapy portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Vida Therapeutics Inc.
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Therapy portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Angion Biomedica Corp.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Therapy portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Daval International Ltd.
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Therapy portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. Corbus Pharmaceuticals, Inc.
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Therapy portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments
    • 9.12. F. Hoffmann-La Roche Ltd.
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Therapy portfolio
      • 9.12.4. Business strategy
      • 9.12.5. Recent developments

Methodology

Free Analysis

Scleroderma is an autoimmune condition that is characterized by hard and thickened skin along with blood vessel problems. Scleroderma is a connective tissue disease that results in an overactive immune system. This condition can also lead to scarring, pain, and inflammation. Scleroderma, a chronic disease, sometimes leads to scarring on kidneys and lungs. It might cause blood vessels to thicken leading to high blood pressure and tissue damage. This condition is not infectious, cancerous, or contagious. Scleroderma symptoms vary from person to person. The effects vary from very mild to serious and life-threatening. The gravity of effects depends on the affected body parts and the extent of alteration. Early and accurate diagnosis followed by effective treatment can curtail the symptoms. The exact cause of scleroderma is still unknown. Factors such as silica exposure, genetic factors, and family history can lead to scleroderma.

There are two types of scleroderma: localized and systemic. In localized scleroderma, the condition is limited to the skin and internal organs are not affected. Apart from the skin, localized scleroderma may also affect underlying muscle and tissue. Localized scleroderma is not fatal; however quality of life is seriously affected due to changes in appearance. Majority of patients develop only a couple of thick patches that appear lighter or darker than surrounding skin.  Localized scleroderma mostly affects children. Localized scleroderma is of four types: morphea, generalized morphea, linear scleroderma, and en coup de sabre. In systemic scleroderma, the condition spreads to visceral organs. The vascular and the immune systems are affected in systemic scleroderma. Blood vessels are also affected leading to spasmodic color changes. This condition is referred to as Raynaud’s phenomenon. Systemic scleroderma is subdivided into two types based on the degree of skin involvement. These two subtypes are diffuse cutaneous scleroderma and limited cutaneous scleroderma.

Global Scleroderma Diagnostics and Therapeutics Market

Around 300,000 people have scleroderma in the United States. Out of these, one-third people have systemic scleroderma. As scleroderma develops progressively and appears in varied forms, it is not very easy to diagnose. Most often, the physicians carry out some tests along with a physical examination. The tests include skin biopsy and blood tests along with a microscopic examination of the skin. The physicians look for symptoms like GERD, skin thickening, shortness of breath, calcium deposits, and joint pain. Currently, a cure for scleroderma doesn’t exist as overproduction of collagen cannot be stopped by any medication. It is, however, possible to treat organ system complications for minimizing damage and maintaining functionality.

Rising incidence of scleroderma and increasing frequency of genetic mutations along with severe environmental changes are the major drivers that will boost the growth of scleroderma diagnostics and therapeutics market. Moreover, the rise in disposable income and increasing awareness regarding preventive healthcare is expected to take the market to new heights. Factors such as extensive R&D related to diagnosis and treatment of scleroderma will create opportunities for the market players. Unfavorable drug effects, ironclad government regulations, high costs related to the diagnosis of scleroderma are some of the factors that will restrict the growth of scleroderma diagnostics and therapeutics market.

The global scleroderma diagnostics and therapeutics market have been segmented into drug class, indication, diagnostic test type, and region. The drug class segment has been segmented into immunosuppressive agents, corticosteroids, endothelin receptor agonists, calcium channel blockers, chelating agents, PDE-5 inhibitors, H2 blockers, prostacyclin analogs, ACE inhibitors, and proton pump inhibitors. Based on the indication, scleroderma diagnostics and therapeutics market have been segmented into systemic and localized. Based on diagnostic test type, scleroderma diagnostics and therapeutics market have been segmented into imaging techniques, skin biopsy, electrocardiogram and echocardiogram, pulmonary function tests, and blood test.

North America will be the dominant region during the forecast period. Rising incidence of scleroderma and availability of latest diagnostics methods will drive the market growth in this region. Europe will be the second largest market. The Asia Pacific is expected to grow at a rapid rate over the forecast period. Extensive research and development activities and increasing awareness will boost the scleroderma diagnostics and therapeutics market in this region. Latin America market will grow at a conservative rate during the forecast period. The Middle East and Africa are expected to experience appreciable growth in the near future.

Some of the key players in the scleroderma diagnostics and therapeutics market include Bayer AG, Allergan, Inc., Active Biotech AB, BioLineRx, Ltd., Digna Biotech, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Vida Therapeutics Inc., Angion Biomedica Corp., Daval International Ltd., Corbus Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd., among others.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com